CTOs on the Move

Cellares

www.cellares.com

 
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.cellares.com
  • 345 Allerton Ave
    South San Francisco, CA USA 94080
  • Phone: 833.235.5273

Executives

Name Title Contact Details

Funding

Cellares raised $18M on 10/29/2020
Cellares raised $832M on 05/05/2021

Similar Companies

Aegerion

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.

Dermira

Dermira is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxford Instruments PLC

Oxford Instruments PLC is a Carteret, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Organix Inc.

Organix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Evolve Biosystems

Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.